LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

Kodu・Aktsiate loetelu・Johnson and Johnson

Johnson and Johnson

Suletud

Sektor Tervishoid

160.15 -0.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

160.04

Max

162.15

Põhinäitajad
By Trading Economics
Sissetulek	-2B 2.7B
Müük	50M 23B
P/E Sektori keskmine	21.72 112.16
Aktsiakasum	2.42
Kasumimarginaal	11.973
Töötajad	131,900
EBITDA	2.1B 7.8B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+10.43 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	21. jaan 2025
Järgmine dividendimakse kuupäev	10. dets 2024
Järgmine aktsia dividendi kuupäev (ex-date)	26. nov 2024

Turustatistika
By TradingEconomics
Turukapital	6.6B 396B
Eelmine avamishind	161.01
Eelmine sulgemishind	160.15

Uudiste sentiment

By Acuity

29%

71%

96 / 389 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

160.9 / 164.1 Toetus ja vastupanu

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2024, 16:07 UTC

Omandamised, ülevõtmised, äriostud

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

15. okt 2024, 19:26 UTC

Tulu

Trending: Johnson & Johnson Posts Higher-Than-Expected Sales

21. okt 2024, 15:26 UTC

Omandamised, ülevõtmised, äriostud

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies -- IBD

21. okt 2024, 09:51 UTC

Peamised uudised

Starboard Targets Another Health Company. Why Kenvue Is in Its Sights. -- Barrons.com

21. okt 2024, 09:30 UTC

Peamised uudised

J&J's Ketamine-Derived Drug Is Taking Off -- WSJ

15. okt 2024, 12:09 UTC

Peamised uudised

Tulu

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15. okt 2024, 12:04 UTC

Tulu

Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered Outlook -- IBD

15. okt 2024, 11:52 UTC

Peamised uudised

Tulu

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15. okt 2024, 10:50 UTC

Tulu

Johnson & Johnson Stock Rises On Q3 Sales Beat And Guidance Raise -- MarketWatch

15. okt 2024, 10:28 UTC

Peamised uudised

Tulu

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Rises. -- Barrons.com

15. okt 2024, 10:25 UTC

Tulu

J&J Reports Strong Earnings but Talc Worries Remain -- Barrons.com

15. okt 2024, 10:20 UTC

Tulu

J&J Earnings Beat Expectations, Aided by Prescription-Drug Sales -- WSJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Cuts 2024 View To Adj EPS $9.88-Adj EPS $9.98 Vs Prior View $9.97-$10.07 >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $9.86-$9.96 Vs Prior View $10.00-$10.10 >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Raises 2024 Adjusted Operational Sales Growth View to 5.7%-6.2% From Prior View 5.5%-6%>JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Updates 2024 Guidance to Reflect Improved Perfromance and Impact From Recent Acquisition of V-Wave >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q U.S. Sales $12.91B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Raises 2024 Operational Sales View to $89.4B-$89.8B Vs Prior View $89.2B-$89.6B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 6.4% in 3Q >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson Raises 2024 View To Sales $88.4B-$88.8B Vs Prior View $88.0B-$88.4B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Adj EPS $2.42 >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson: Innovative Medicine 3Q Results Driven by Key Brands Such as DARZALEX, ERLEADA, TREMFYA and SPRAVATO and Continued Uptake From Recently Launched Products Including CARVYKTI, RYBREVANT, TECVAYLI and TALVEY, With 11 Assets Delivering Double-Digit Growth >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q International Sales $9.56B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $14.58B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Sales $22.47B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q EPS $1.11 >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15. okt 2024, 10:20 UTC

Tulu

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

10.43% tõus

12 kuu keskmine prognoos

Keskmine 178.45 USD 10.43%

Kõrge 215 USD

Madal 159 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Johnson and Johnson aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

160.9 / 164.1Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

96 / 389 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.